Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
Key Financial Performance
Mean annualized eGFR slope Positive mean annualized eGFR slope of almost 2 observed at 52 weeks across all 32 dose patients in the STAAR study. This is a significant improvement compared to the average untreated Fabry patient who experiences an annual decline in eGFR slope of minus 3 or minus 4. The improvement is attributed to the investigational gene therapy ST-920.
Annualized eGFR slope for 2-year follow-up Positive annualized eGFR slope of 1.7 observed for the 19 patients who have achieved 2 years of follow-up. This improvement is remarkable compared to the decline observed in untreated patients and is due to the effects of ST-920.
Durability of alpha-Gal A activity Elevated expression of alpha-Gal A activity maintained for up to 4.5 years for the longest treated patient. This durability is a result of the ST-920 treatment.
Plasma lyso-Gb3 levels Plasma lyso-Gb3 levels remained generally stable following the withdrawal of enzyme replacement therapy (ERT). Stability is attributed to the effects of ST-920.
Cardiac endpoints Stabilization in cardiac function and morphological and biomarker data observed in 32 patients with 52 weeks of follow-up. This includes stable left ventricular mass, left ventricular ejection fraction, and cardiac biomarkers such as troponin and NT-proBNP. Stability is significant as cardiac function in Fabry patients typically declines over time.
Quality of life scores Statistically and clinically significant improvement in SF-36 quality of life scores, including a change of +15 in the role-physical score, +10 in the vitality score, and +9 in the bodily pain score at 52 weeks compared to baseline. Improvement is due to the benefits of ST-920.
Gastrointestinal symptom rating scale Statistically significant improvement compared to baseline observed in the gastrointestinal symptom rating scale. Improvement is attributed to ST-920.
ERT withdrawal All patients who came into the study on ERT were able to safely withdraw from ERT, with one patient off ERT for more than 3 years, avoiding over 1,000 biweekly ERT infusions. This is due to the efficacy of ST-920.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Fabry Disease Treatment (ST-920): Positive top-line results from the Phase 1/2 STAAR study. Observed a positive mean annualized eGFR slope of almost 2 at 52 weeks across all 32 patients. FDA agreed to use mean eGFR slope as the primary basis for accelerated approval. Secondary endpoints, including cardiac stabilization and quality of life improvements, were also positive. The treatment was well-tolerated without preconditioning.
Neurology Genomic Medicine (ST-503): Initiated the first clinical site for the Phase 1/2 STAND study for chronic neuropathic pain. Preclinical data showed significant pain reduction in animal models. First patient dosing expected in fall 2025, with preliminary efficacy data anticipated in Q4 2026.
Prion Disease Treatment (ST-506): Progress in preclinical studies with productive discussions with the U.K.'s MHRA. Anticipated CTA submission by mid-2026. Preclinical data showed brain-wide suppression of prion protein expression and survival benefits in animal models.
Fabry Commercialization Agreement: Actively seeking a commercialization partner for Fabry disease treatment. Equity offering completed earlier this quarter to support operations until Q4 2025.
Cash Runway: Current cash runway expected to fund operations into Q4 2025. Focused on securing long-term funding and partnerships.
Neurology Genomic Medicine Expansion: Transitioned to a clinical-stage neurology genomic medicine company with the initiation of the STAND study for chronic neuropathic pain.
Business Development: Engaging in broader business development discussions across the pipeline and platforms, including the MINT platform.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cash runway and funding challenges: The company’s current cash runway is expected to fund operations only into the fourth quarter of 2025. There is a critical need to secure a Fabry commercialization partner and address long-term funding needs to support the neurology genomic medicine pipeline.
Regulatory and approval risks: The company’s plans for regulatory submissions, including the BLA submission for ST-920 under the accelerated approval pathway, are subject to successful engagement with the FDA and other regulatory bodies. Any delays or issues in these processes could impact timelines and approvals.
Dependence on partnerships: The company is highly reliant on securing a Fabry commercialization agreement and other strategic partnerships to ensure financial stability and advance its pipeline. Failure to establish these partnerships could hinder progress.
Market competition: The company faces competitive pressures from existing treatments for Fabry disease, such as Replagal, Fabrazyme, and Galafold, which have established market presence and efficacy data.
Clinical trial risks: The success of ongoing and planned clinical trials, including the Phase 1/2 STAND study and the prion disease program, is critical. Any setbacks in patient enrollment, data generation, or safety concerns could delay progress.
Economic and operational environment: The company is operating in a challenging environment, which could impact its ability to advance its pipeline and secure necessary resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fabry Disease Program: Sangamo plans to submit a Biologics License Application (BLA) for ST-920 under the accelerated approval pathway as early as Q1 2026. The company is engaging with the FDA and anticipates sharing additional clinical data at the ICIEM2025 conference in September 2025. The program has shown positive results, including stabilization in cardiac endpoints and broader quality of life improvements.
Neurology Genomic Medicine Program: The company initiated its first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain. Sangamo expects to dose the first patient in fall 2025 and anticipates preliminary proof of efficacy data by Q4 2026. The program targets the SCN9A gene and has shown promising preclinical results.
Prion Disease Program: Sangamo plans to submit a Clinical Trial Application (CTA) for ST-506 as early as mid-2026. The program has demonstrated significant survival benefits in preclinical models and is progressing towards GLP toxicology studies.
Financial Guidance: The company completed an equity offering and expects its current cash runway to fund operations into Q4 2025. Sangamo is actively seeking a Fabry commercialization partner and exploring broader business development opportunities to address long-term funding needs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Has the team already held the pre-BLA meeting with the FDA to discuss the potential path to approval using the 1-year eGFR data as a predictor for the 2-year eGFR benefit?
A:The team has not yet held the pre-BLA meeting as it is not the right time. They plan to hold it in the future. Previously, the FDA agreed on accelerated approval with 1-year eGFR data and suggested submitting 2-year data when available. Currently, there are 32 patients with 1-year data and 19 with 2-year data, which are complementary.
Q:What additional insights should be anticipated at the upcoming SSIEM presentation?
A:The presentation will include top-line data with additional details compared to the June press release. However, individual patient data will not be shown. More details on endpoints will be provided, and the data will be available on the company’s website after the embargo lifts.
Q:How does ST-503's efficacy in Nav1.7 compare to recent small molecule Nav1.8 inhibitors?
A:The company believes Nav1.7 is the right target due to its fundamental control of pain signals. Evidence includes individuals with Nav1.7 mutations who feel no pain, unlike Nav1.8 mutations. Recent Nav1.8 trial outcomes have strengthened their conviction in Nav1.7. The study is in the activation phase, and they aim to show suppression of pain in a dose-range finding study.
Q:Have you conducted surveys with patients or physicians to understand the potential adoption rate of the current product profile?
A:Patient advocacy groups and physicians are enthusiastic about the product due to its potential to improve quality of life with a one-time injection compared to the burdensome biweekly infusions of the current standard of care. Patients and physicians are eager for approval, and the adoption rate is expected to be high.
Q:What are potential partners looking for beyond the shared data?
A:Potential partners are excited about the data and convinced of the product's safety and effectiveness. They seek stability in the regulatory environment and assurance on CMC agreements. The compressed timeline for BLA submission has led to many interactions and data points, which partners find reassuring.
Q:What data points should be expected for the pain program and Fabry update in September?
A:The pain program will present preclinical data, including GLP tox study results in NHP and mouse data. For Fabry, additional details on endpoints and safety/efficacy data will be shared.
Q:How will the initiation of the STAND trial impact cash burn, and are there updates on the MINT platform?
A:The company plans to continue the Nav1.7 program and dose patients as intended. Finding a Fabry commercialization partner is a priority to address funding needs. Updates on the MINT platform include improved integration rates in primary cell types, with ongoing discussions for collaborations.
Q:What kind of data should be expected from the STAND trial by the end of next year?
A:Safety data and early efficacy data from the dose escalation trial will be available. The 12-week endpoint will include standard pain study scores, sleep assessment scores, and suicidality scores. Long-term benefits of Nav1.7 as a genomic medicine are anticipated.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about whether potential partners are looking for anything beyond the shared data. While they expressed confidence in the data and regulatory stability, they did not provide specific details on additional partner requirements or expectations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CTA submission
Corporate Communications
Dubois Stringfellow
ERT patient
FDA mean
Gal
Gb level
International Congress
MHRA
Nathalie Dubois
Research Division
STAAR study
Senior VP
Unidentified
Wilkie Head
death
disease patient
initiation site
line readout
line result
mass
medicine initiation
meeting UK
nonhuman primate
patient ERT
patient study
safety study
site Phase
stabilization
study ERT
study FDA
track
SGMO Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call highlights financial and strategic challenges, including NASDAQ delisting and funding needs, which overshadow progress in clinical trials. The Q&A reveals uncertainties in business development and data disclosure timelines. Despite some positive regulatory signals, the overall sentiment is negative due to financial instability and execution risks.
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
SGMO Slides
SGMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
